Skip to main content
Clinical Trials/IRCT20181224042104N1
IRCT20181224042104N1
Recruiting
Phase 2

Determination of efficacy and safety of adding Oxaliplatin to neoadjuvant chemotherapy in locally advanced breast cancer patients

Shiraz University of Medical Sciences0 sites30 target enrollmentTBD

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Not specified
Sponsor
Shiraz University of Medical Sciences
Enrollment
30
Status
Recruiting
Last Updated
7 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
7 years ago
Study Type
Interventional
Sex
Female

Investigators

Eligibility Criteria

Inclusion Criteria

  • Histologically confirmed locally advanced breast cancer
  • Clinical stage T3, T4, and/or N2, N3
  • Patients with Eastern Cooperative Oncology Group performance status of 0 or 1
  • Absolute neutrophil count \> 1500/ mm3
  • Hemoglobin \> 8\.0 g/dL
  • Platelet count \> 100,000/mm3
  • Creatinine \< 2\.5 times the upper limit of normal (ULN)
  • Serum transaminases \< 2\.5 times ULN
  • Serum alkaline phosphatase \< 4 times ULN
  • Total bilirubin \< 2\.5 times

Exclusion Criteria

  • Active infection
  • Other primary malignancy
  • Any documented distant metastasis
  • Uncontrolled systemic diseases (including severe cardiovascular, kidney and liver disease)
  • Patients refusal to participate in the trial

Outcomes

Primary Outcomes

Not specified

Similar Trials